Dr. Patrice Hugo recently co-authored a white paper with IQVIA about restarting clinical trials in Asia Pacific following the COVID-19 pandemic. The recent restrictions imposed by many countries in response to the COVID-19 outbreak has impacted ongoing clinical research, and restarting clinical trials is a critically important activity. This paper investigates how research sites are utilizing a variety of measures, including diagnostic tests, in an attempt to minimize risk of external transmission of the infection to staff and patients at the site.
Complete the form below to access this white paper
Related Insights
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
Vaccine Testing for SARS-CoV-2
ELISA and Viral Neutralization Assays
Keeping Up with the Flu: Advances in seasonal influenza vaccine development
Vaccine Laboratory Services
Combating Emerging and Re-Emerging Infectious Diseases in Clinical Trials by Harnessing Innovative Technologies
Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases
Tools for better management of infectious disease clinical trials
Zika Vaccine Research: Complex Steps Toward a Critical Need
Overcoming Zika vaccine development challenges
Vaccine Testing Capabilities
End-to-end laboratory for clinical vaccine development
